全文获取类型
收费全文 | 214篇 |
免费 | 5篇 |
国内免费 | 5篇 |
专业分类
儿科学 | 4篇 |
妇产科学 | 5篇 |
基础医学 | 5篇 |
口腔科学 | 2篇 |
临床医学 | 18篇 |
内科学 | 17篇 |
神经病学 | 10篇 |
特种医学 | 1篇 |
外科学 | 19篇 |
综合类 | 29篇 |
预防医学 | 5篇 |
药学 | 89篇 |
中国医学 | 5篇 |
肿瘤学 | 15篇 |
出版年
2023年 | 2篇 |
2022年 | 5篇 |
2021年 | 1篇 |
2020年 | 1篇 |
2019年 | 3篇 |
2018年 | 5篇 |
2017年 | 3篇 |
2015年 | 3篇 |
2014年 | 12篇 |
2013年 | 20篇 |
2012年 | 10篇 |
2011年 | 2篇 |
2010年 | 9篇 |
2009年 | 5篇 |
2008年 | 5篇 |
2007年 | 9篇 |
2006年 | 3篇 |
2005年 | 4篇 |
2004年 | 6篇 |
2003年 | 10篇 |
2002年 | 3篇 |
2001年 | 6篇 |
2000年 | 2篇 |
1999年 | 5篇 |
1998年 | 2篇 |
1997年 | 5篇 |
1996年 | 5篇 |
1995年 | 2篇 |
1994年 | 8篇 |
1993年 | 9篇 |
1992年 | 2篇 |
1991年 | 10篇 |
1990年 | 5篇 |
1989年 | 5篇 |
1988年 | 3篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1985年 | 5篇 |
1984年 | 3篇 |
1983年 | 2篇 |
1982年 | 5篇 |
1980年 | 5篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1976年 | 3篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有224条查询结果,搜索用时 15 毫秒
1.
2.
Simona Cabib Claudio Castellano Vincenzo Cestari Umberto Filibeck Stefano Puglisi-Allegra 《Psychopharmacology》1991,105(3):335-339
Pretreament with small, per se ineffective doses of the selective D1 antagonist SCH 23390 inhibited hyperactivity induced by cocaine. On the other hand, the classic neuroleptic haloperidol and the selective D2 antagonist metoclopramide prevented the stimulatory effects of cocaine on locomotion only at hypokinetic doses, while the atypical neuroleptic (–)-sulpiride, a selective D2 antagonist, did not produce significant effects when administered at the hypokinetic dose of 12 mg/kg. Finally, at low doses (–)-sulpiride dose-dependently potentiated the locomotor-stimulating effects of cocaine, an effect that is not shared either with haloperidol or with metoclopramide. These results are discussed in terms of different roles of DA receptor subtypes in the modulation of the stimulant effects of cocaine on locomotion. 相似文献
3.
Ch. Ell J. Braun H. J. König S. Domschke W. Domschke 《Journal of molecular medicine (Berlin, Germany)》1985,63(12):572-574
Summary The pharmacokinetics of high-dose metoclopramide (10 mg/kg body wt. in five infusions of 2 mg/kg body wt. each) was studied in 11 patients (5 females, 6 males) in two groups: group A with and group B (consisting of five patients) without forced diuresis. When the drug was infused, forced diuresis had no influence on the pharmacokinetics of metoclopramide (serum level after the 1st infusion was 851±361 ng/ml in group A versus 840±348 ng/ml in group B; after the 5th infusion it was 2,005±588 ng/ml in group A versus 2,463±1,350 ng/ml in group B). There were significant differences in the 24-h serum levels (582±308 ng/ml in group A versus 379±170 ng/ml in group B;P<0.05) and in the elimination half life (8.5±2.6 h in group A versus 6.1±1.1 h in group B;P<0.05). The results demonstrate that the dosage regimen originally suggested by Gralla for cytostatic drugs, with forced diuresis for high-dose metoclopramide therapy, may also be applied, with no dosage reduction, with to other cytostatic drugs which do not require forced diuresis. 相似文献
4.
5.
T. M. MacDonald 《European journal of clinical pharmacology》1991,40(3):225-230
Summary The effects of oral doses of the dopamine antagonist antiemetics metoclopramide and domperidone on baseline and dopamine stimulated renal function and systemic haemodynamics were assessed in a placebo controlled crossover study in 9 healthy volunteers.Metoclopramide did not change baseline ERPF, GFR or FF over 2 h post dosing but it significantly reduced baseline UNaV, UKV, urine flow, urinary dopamine excretion, supine and erect diastolic blood pressure and supine systolic blood pressure. Domperidone and placebo did not cause these effects.Metoclopramide caused a marked rise and domperidone a small fall in plasma aldosterone concentration (PAC) but placebo was without effect. Neither antiemetic altered plasma renin activity (PRA) but a small fall occurred with placebo.Two hours after pretreatment with placebo dopamine (2 g/kg/min) increased effective renal plasma flow (ERPF), glomerular filtration rate (GFR), sodium excretion rate (UNaV), urine flow rate, urinary dopamine excretion rate, supine systolic blood pressure and supine and erect pulse rate and decreased the potassium excretion rate (UKV), filtration fraction (FF) and supine diastolic blood pressure.Metoclopramide pretreatment, did not attenuate the dopamine induced rise in ERPF, GFR, urine flow, urinary dopamine excretion or supine systolic blood pressure but it did attenuate the rise in pulse rate, the fall in diastolic pressure, and the antikaliuretic effect of dopamine leading to a net kaliuresis when compared to placebo. Domperidone was similar to placebo.Neither metoclopramide nor domperidone given orally caused clinically important antagonism of the renal haemodynamic effects of dopamine. However the effects of metoclopramide on blood pressure and electrolyte excretion may have clinical importance.Metoclopramide has significant pharmacodynamic effects which are probably not due to DA2 antagonism but may be mediated by DA1 antagonism or be non-specific.Abbreviations DA
dopamine
- ERPF
effective renal plasma flow
- FF
filtration fraction
- GFR
glomerular filtration rate
- PAC
plasma aldosterone concentration
- PRA
plasma renin activity
- UV
urine flow rate
- UNaV
urinary sodium excretion rate (natriuresis)
- UKV
urinary potassium excretion rate (kaliuresis)
- HPLC
high performance liquid chromatography. 相似文献
6.
Certain drugs, particularly clozapine and clonidine, have been reported to increase selectively the latency to initiate brain stimulation (the ON latency) in a shuttlebox test of self-stimulation, suggesting a preferential attenuation of the "reward" component. The pharmacological selectivity of this reported effect was systematically evaluated. At doses that blocked bar-pressing self-stimulation, metoclopramide (3 mg/kg), prazosin (3 mg/kg) clonidine (0.1mg/kg), clozapine (3 mg/kg)and haloperidol (0.3 mg/kg), all elevated the ON latency to a greater extent than the OFF latency. Methocarbamol (200 mg/kg), and a muscle relaxant, also elevated the ON latency preferentially but the magnitude of this preferential effect was smaller than that produced by the other drugs. A hurdle in the center of the shuttlebox increased the ON and OFF latencies nonselectively. The shuttlebox procedure does not clearly discriminate among various substances that interfere with noradrenergic or dopaminergic neurotransmission, but the common profile produced by the these substances is distinguishable to some degree from simple motor disruption. 相似文献
7.
目的:考察盐酸曲马多注射液与盐酸甲氧氯普胺注射液在静脉镇痛泵中的配伍稳定性。方法:在室温条件下,观察与测定盐酸曲马多注射液与盐酸甲氧氯普胺注射液在静脉镇痛泵中配伍后的外观、不溶性微粒及pH值变化,并用高效液相色谱法测定配伍液中二者的含量变化。结果:室温72h内,盐酸曲马多与盐酸甲氧氯普胺在静脉镇痛泵(0.9%氯化钠注射液)中混合后的外观、pH、不溶性微粒、含量均无明显变化。结论:在室温条件下,盐酸曲马多注射液与盐酸甲氧氯普胺注射液在静脉镇痛泵中混合后72h内均保持稳定。 相似文献
8.
小鼠胃排空及小肠推进实验方法的探讨 总被引:16,自引:0,他引:16
目的 改进小鼠胃排空及小肠推进的实验方法。方法 采用营养性半固体黑色糊同时测定小鼠胃排空及小肠推进。结果 本实验方法可同时观察药物对胃排空和小肠推进的影响。结论 本方法能反映药物对胃肠运动的影响 ,节省动物 ,提高实验效率。 相似文献
9.
《International Journal of Obstetric Anesthesia》2014,23(2):131-137
BackgroundMetoclopramide and magnesium sulfate are extensively used agents in obstetrics. In this study, the relaxant properties of metoclopramide and magnesium sulfate on pregnant myometrium, together with the possible reversing influences of oxytocin and cabergoline (a dopamine D2 receptor agonist), were investigated.MethodsMyometrial strips from 24 parturients were randomly allocated to four groups: control (Group CON), magnesium sulfate and oxytocin (Group MSO), metoclopramide and oxytocin (Group MEO), and metoclopramide and cabergoline (Group MEC). Myometrial strips were mounted on a myograph bathed in Krebs buffer. Saline (Group CON) and five incremental doses of magnesium sulfate (Group MSO) or metoclopramide (Groups MEO and MEC) were sequentially microinjected into the bath. Subsequently, oxytocin (Groups CON, MSO and MEO) or cabergoline (Group MEC) was microinjected into the bath. The myometrial contractile characteristics after each drug injection, including contractile force, interval and duration, were analyzed.ResultsMagnesium sulfate was more potent for prolonging myometrial contractile interval than reducing contractile force. Metoclopramide relaxed myometrial contractions by inhibiting contractile force and prolonging contractile interval in a concentration-dependent manner. Oxytocin reversed both the inhibited contractile force and the prolonged contractile interval caused by a high concentration of magnesium sulfate but accelerated the contractile interval and had no significant effect on the contractile force suppressed by metoclopramide. The relaxant effects of metoclopramide were completely reversed by cabergoline.ConclusionsBoth magnesium sulfate and metoclopramide relaxed myometrial contractions, and exhibited different responses to subsequent oxytocin treatment. The relaxant mechanism of metoclopramide may be via blockade of dopamine D2 receptor, which requires further investigation. 相似文献
10.
《Pharmaceutical development and technology》2013,18(5):1122-1130
Metoclopramide HCl (MTC) is commonly used for the management of gastrointestinal disorders. It has a short biological half-life and is usually administered four times daily to maintain effective concentrations throughout the day. The aim of this study is to develop sustained-release hydrophilic matrix tablet formulations of drug to achieve reproducible and predictable release rates, extended duration of activity, decreased toxicity, reduction of required dose, optimized therapy, and improved patient compliance. Hydroxypropylmethyl cellulose (HPMC), carboxymethylcellulose sodium (NaCMC), chitosan and Carbopol 981 were incorporated in the matrix system separately or in combinations as release controlling factor by direct compression technique. Compatibility among the formulation components was assessed by DSC and FTIR analysis. MTC release from matrix was evaluated by using the US Pharmacopeia dissolution apparatus II. All formulations met the criteria of pharmacopeial requirements. Dissolution studies show that polymer type and concentration are important parameters on drug release. Chitosan, carbopol and NaCMC formulations exhibited pH-dependent drug release profile whereas HPMC did not. All the formulations containing 1:1 ratio of HPMC and chitosan exhibited desired drug release showing that all active substance releases progressively in a period of whole dissolution time and therefore it can be regarded as worthy of consideration for the manufacture of sustained-release MTC product. 相似文献